Journal: The Journal of Clinical Investigation

Article Title: Lymphatic drainage from bronchus-associated lymphoid tissue in tolerant lung allografts promotes peripheral tolerance

doi: 10.1172/JCI136057

Figure Lengend Snippet: Intravital 2-photon imaging of (A) retransplanted (Retxp) tolerant BALB/c lung allograft (n = 2) and (B) BALB/c cardiac allograft (n = 2) 6 days after transplantation of BALB/c heart into a B6 mouse into which a tolerant BALB/c lung was retransplanted 7 days prior and received VEGF-C156S between the time of lung retransplantation and heart transplantation (Foxp3+ cells: green; quantum dot–labeled [q-dot–labeled] vessels: red; second harmonic generation [SHG]: blue). The BALB/c lung had been originally transplanted into a B6 Foxp3 IRES-GFP mouse (treated with perioperative costimulatory blockade [CSB]) at least 30 days before the retransplant procedure. (C) Quantification of density of Foxp3-GFP cells in BALB/c hearts (up to 5 separate areas/graft were examined) 6 days after transplantation (Txp) into B6 recipients of tolerant BALB/c lung allografts, that received no treatment or were treated with VEGF-C156S for 7 days before cardiac transplantation. Data are expressed as mean ± SEM. Mann-Whitney U test was used to compare the means. (D) Kaplan-Meier survival curves of BALB/c hearts that were transplanted into nonimmunosuppressed B6 mice, (●) untreated (n = 7) or (▲) treated with VEGF-C156S (n = 4), that received tolerant BALB/c pulmonary allografts 7 days before cardiac transplantation. The BALB/c lungs had been originally engrafted into B6 mice that received perioperative costimulatory blockade and then retransplanted at least 30 days later. (E) Histological appearance (H&E) of long-term-surviving BALB/c hearts after transplantation into VEGFC-156S–treated B6 mice into which a tolerant BALB/c lung allograft was retransplanted 7 days prior. Scale bars: 30 μm (A and B) and 100 μm (E).

Article Snippet: Media (600 μL) containing CCL22 (10 ng/mL) (R&D Systems) or VEGF-C156S (1 or 10 ng/mL) (R&D Systems) or control media were added to the bottom wells.

Techniques: Imaging, Transplantation Assay, Labeling, MANN-WHITNEY

Journal: bioRxiv

Article Title: Contractile reprogramming of cardiac pericytes by MEK inhibition promotes arteriologenesis of the ischemic heart

doi: 10.1101/2020.11.10.376772

Figure Lengend Snippet: (A) Immunofluorescence images showing expression of VSMC markers by naïve and differentiated PCs when cultured with different combinations of GFs for ten days. All GFs : VEGF, IGF-1, EGF, bFGF. No GFs : depletion of all GFs. -EGF/bFGF : only VEGF and IGF1. + EGF/bFGF : only EGF and bFGF. (B) Transcriptional analysis of SM-genes. mRNA data are expressed as fold change of CASMCs used as reference (dashed line at y=1). (C) Western blotting analysis of VSMC markers. Blots show a representative PC line. Graphs report blots densitometry. N=5. Values are means ± SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.

Article Snippet: Stimuli used to induce cell migration were recombinant human VEGF-A (10 ng/mL), human SDF1α (100 ng/mL) and human PDGF-BB (20 ng/mL) (all from Peprotech).

Techniques: Immunofluorescence, Expressing, Cell Culture, Western Blot

Journal: bioRxiv

Article Title: Contractile reprogramming of cardiac pericytes by MEK inhibition promotes arteriologenesis of the ischemic heart

doi: 10.1101/2020.11.10.376772

Figure Lengend Snippet: A) Phospho-Kinase array with human cardiac PCs. For a quick screening of the intracellular signalling activated by EGF and bFGF but not by VEGF and IGF1 in cardiac PCs, a human phospho-Kinase protein array was performed (N=2 PCs). The array allowed the detection of the phosphorylation of 43 kinases (R&D ARY003B). We report the main results of the screening, the membranes and densitometry graphs. (B) A subsequent western blot analysis confirmed the activation of EGFR-FGFR-ERK1/2 signalling by EGF and bFGF in cardiac PCs. N=3. A, B, C are different donors.

Article Snippet: Stimuli used to induce cell migration were recombinant human VEGF-A (10 ng/mL), human SDF1α (100 ng/mL) and human PDGF-BB (20 ng/mL) (all from Peprotech).

Techniques: Protein Array, Western Blot, Activation Assay